Searching for Answers: June 2014

In one of their "Room for Debate" features, The Opinion Pages of The New York Times

June 17 chose five mostly HIV-AIDS Industry likely suspects to "debate" use of Gilead's toxic chemotherapy Truvada for so-called "PrEP."
Is a Pill Enough to Fight H.I.V.?http://www.nytimes.com/roomfordebate/2014/06/17/is-prep-a-good-way-to-fight-hiv-infections?hp&rref=opinion
It wasn't much of a "debate," more akin to: "French fries: possibly fattening, pretty much OK, or really f'king great?" The missing position:"You're poisoning yourself, stupid!"

Extended interview with Dr. James Chin, former Chief of Global HIV Surveillance for the World Healt

James (Jim) Chin has been at the forefront of public health epidemiology for decades. He works in public health surveillance and prevention of communicable diseases. He has studied the AIDS pandemic from the early 1980s in California – where he was responsible for surveillance and control of communicable diseases – to the late 1980s at the World Health Organization in Geneva, Switzerland, where he was responsible for developing the methods and guidelines for global and regional HIV/AIDS surveillance. During his public health career, he has held leadership positions at state, national, and International organizations and received recognition for his work as an infectious disease epidemiologist. Since his resignation from the WHO Global Programme on AIDS in 1992, he has worked as an independent consultant for different international agencies to evaluate the patterns and prevalence of HIV in developing countries – primarily in Africa and Asia. Dr. Chin’s book The AIDS Pandemic: The Collision of Epidemiology with Political Correctness (2006), takes a critical look at HIV/AIDS estimates and the international response to AIDS.

Searching for Answers

Wednesday, June 18, 2014

A New York Times opinion section "debate" about Truvada and so-called "Pre-Exposure Prophylaxis" or "PrEP."

Total Pageviews

Available for Speaking Engagements

My Blog